Intestinal Research
Cure8 research brief
The JAK attack: transforming the management of ulcerative colitis in India
Medications
Tofacitinib
Corticosteroids
Steroids
JAK inhibitor
Clinical study
Clinicians
Researchers
Why This Matters
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could change practical treatment choices and outcomes.
Who Should Pay Attention
Clinicians treating UC in India, adult patients with moderate-to-severe UC (including steroid-dependent or refractory cases), researchers studying real-world IBD treatment, and policy makers interested in access/cost of advanced therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review summarizes published and real-world experience from India showing tofacitinib used across many UC presentations — including steroid-dependent/refractory disease, acute severe UC, proctitis, and elderly-onset UC.
The authors highlight practical advantages: oral dosing, rapid onset, predictable pharmacokinetics, and availability of generics that help overcome barriers to advanced therapies in resource-limited settings.
The article frames tofacitinib not just as an effective agent but as a drug that has helped align Indian UC care with international treatment goals (for example, deeper remission endpoints such as histologic healing) and reduced reliance on corticosteroids.
If you are reading this as a patient, clinician, or researcher, note that the piece is a review focused on the Indian context and synthesizes accumulating real-world data rather than reporting a single new clinical trial.
Keep In Mind
This article is a review/abstract from Intestinal Research drawing on published and real-world Indian experience; it synthesizes existing evidence rather than presenting a new randomized trial. Safety, individual suitability, and regulatory guidance should be discussed with treating clinicians.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationIntestinal Research
PublisherKorean Association for the Study of Intestinal Diseases
AuthorsArshdeep Singh, Arshia Bhardwaj, Vandana Midha +1 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 30, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
Tofacitinib FDA label update (2026-07-27)
This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...
IBD and Pregnancy Risks: Few Women Discuss Contraception With Their IBD Specialist
Pregnancy planning and contraception are important for people with IBD because active disease at conception is linked to worse pregnancy outcomes. The article shows many women with IBD are unsure about how contraception...